Mebendazole survival benefit.
The median progression-free survival (PFS) was 13.1 months for patients who received mebendazole for more than 1 month, compared with 9.2 months for those who received less than 1 month of the drug.
The survival benefits of the anthelmintic drug mebendazole (MBZ) have been extensively evaluated in both preclinical animal models and human clinical trials, demonstrating a significant ability to extend life and delay disease progression in several contexts, though long-term human data remain mixed.
Preclinical Animal Models. In laboratory models, mebendazole has consistently demonstrated the ability to extend overall survival, particularly in notoriously difficult-to-treat brain cancers:
Glioblastoma (GBM): In mouse glioma models, oral mebendazole significantly extended mean survival by up to 63%, increasing the lifespan from 30 days in control mice to 49 days in treated mice. In human GBM xenograft models, MBZ prolonged mean survival from 48 days to 65 days. Furthermore, combining mebendazole with the standard chemotherapy drug temozolomide (TMZ) resulted in a 72.4% improvement in survival, extending lifespan to 50 days compared with 41 days for TMZ alone.
Malignant Meningioma: In an intracranial mouse model of Grade III malignant meningioma, mebendazole monotherapy increased median survival by 58% (from 19 days to 30 days). When combined with a single dose of radiation, the median survival increased by 105% (to 39 days), demonstrating a powerful synergistic survival benefit.
Human Clinical Trials In humans, mebendazole has shown preliminary success in extending Progression-Free Survival (PFS)—the length of time a patient lives with the disease without it worsening—though evidence for extending Overall Survival (OS) is more complex:
High-Grade Gliomas: A Phase 1 clinical trial evaluating mebendazole in combination with standard temozolomide for newly diagnosed high-grade gliomas reported a median overall survival of 21.0 months. Impressively, 41.7% of the patients were still alive at 2 years, and 25% remained alive at 3 and 4 years, with six patients surviving past 4 years of therapy. The median progression-free survival (PFS) was 13.1 months for patients who received mebendazole for more than 1 month, compared with 9.2 months for those who received less than 1 month of the drug.
Metastatic Colorectal Cancer (mCRC): A randomized, double-blind, placebo-controlled trial investigated mebendazole added to standard therapies (FOLFOX4 and bevacizumab) in 40 mCRC patients. The mebendazole group experienced a drastic, statistically significant improvement in median progression-free survival (PFS), achieving 9.25 months compared to just 3 months in the control group. Despite this remarkable delay in disease progression, the 1-year overall survival (OS) rate did not differ statistically between the two groups (75% for MBZ vs. 60% for control).
Advanced Gastrointestinal Cancers: Not all trials have yielded positive survival outcomes. A Swedish Phase 2a trial evaluating mebendazole as a monotherapy for advanced, refractory gastrointestinal cancer or cancer of unknown origin was terminated early due to a lack of efficacy and rapid disease progression in the participants.
Case Reports and Real-World Evidence Beyond formal trials, extraordinary survival benefits have been documented in isolated case reports and real-world cohort studies:
Case Reports: A 48-year-old man with treatment-refractory metastatic adrenocortical carcinoma experienced 19 months of stable disease on mebendazole monotherapy, a significant extension for a disease that had progressed through all other systemic therapies. Similarly, a 74-year-old patient with progressing metastatic colon cancer achieved near-complete remission of lung and lymph node metastases after 6 weeks of mebendazole.
Real-World Observational Cohort: A recent study tracking 197 cancer patients using a telemedicine-prescribed combination of ivermectin and mebendazole found that at a 6-month follow-up, 48.4% of respondents reported either tumor regression or no current evidence of disease, and an additional 36.1% reported stable disease. While these results rely on self-reported outcomes without radiographic confirmation, they suggest a high clinical benefit ratio in a real-world setting.